Advertisement

Current Oncology Reports

, 21:5 | Cite as

Management of Residual Mass in Germ Cell Tumors After Chemotherapy

  • Costantine AlbanyEmail author
  • Kenneth Kesler
  • Clint Cary
Genitourinary Cancers (DP Petrylak and JW Kim, Section Editors)
  • 51 Downloads
Part of the following topical collections:
  1. Topical Collection on Genitourinary Cancers

Abstract

Purpose of Review

The purpose of this review is to educate medical oncologists on the management of patients with residual germ cell tumors and the role of surgical resection after platinum-based chemotherapy.

Recent Findings

Patients with non-seminomatous testicular cancer and residual enlarged retroperitoneal lymph nodes > 1 cm following induction chemotherapy with normal tumor markers should undergo a post-chemotherapy retroperitoneal lymph node dissection. All patients with primary mediastinal non-seminoma should undergo surgical resection of the mediastinal mass post-chemotherapy. These are complex surgeries and require expert surgeons in high-volume centers. Patients with advanced testicular seminoma who have residual masses less than 3 cm after chemotherapy can be observed without further intervention. Patients with a residual mass > 3 cm should be evaluated with PET scan after 6 weeks of chemotherapy. Residual mass with negative PET scan can be followed by surveillance while a positive PET scan requires further work up to rule out active disease.

Keywords

Chemotherapy Residual mass Testis cancer Primary mediastinal Germ cell tumor Retroperitoneal lymph node dissection Seminoma Non-seminoma Teratoma 

Notes

Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Hendry WF, Norman AR, Dearnaley DP, Fisher C, Nicholls J, Huddart RA, et al. Metastatic nonseminomatous germ cell tumors of the testis: results of elective and salvage surgery for patients with residual retroperitoneal masses. Cancer. 2002;94:1668–76.CrossRefGoogle Scholar
  2. 2.
    Heidenreich A, Pfister D, Witthuhn R, Thüer D, Albers P. Postchemotherapy retroperitoneal lymph node dissection in advanced testicular cancer: radical or modified template resection. Eur Urol. 2009;55:217–24.CrossRefGoogle Scholar
  3. 3.
    • Cho JS, Kaimakliotis HZ, Cary C, et al. Modified retroperitoneal lymph node dissection for post-chemotherapy residual tumour: a long-term update. BJU Int. 2017;120:104–8 This study reported long-term outcomes of modified-template post-chemotherapy retroperitoneal lymph node dissection in selected patients with low-volume metastatic non-seminomatous germ cell tumour and showed durable long-term efficacy without risk of in-field recurrences.CrossRefGoogle Scholar
  4. 4.
    Carver BS, Shayegan B, Serio A, Motzer RJ, Bosl GJ, Sheinfeld J. Long-term clinical outcome after postchemotherapy retroperitoneal lymph node dissection in men with residual teratoma. J Clin Oncol. 2007;25:1033–7.CrossRefGoogle Scholar
  5. 5.
    Beck SD, Foster RS, Bihrle R, et al. Long-term outcome for patients with high volume retroperitoneal teratoma undergoing post-chemotherapy surgery. J Urol. 2009;181:2526–32.CrossRefGoogle Scholar
  6. 6.
    Ehrlich Y, Brames MJ, Beck SD, et al. Long-term follow-up of cisplatin combination chemotherapy in patients with disseminated nonseminomatous germ cell tumors: is a postchemotherapy retroperitoneal lymph node dissection needed after complete remission? J Clin Oncol. 2010;28:531–6.CrossRefGoogle Scholar
  7. 7.
    Kollmannsberger C, Daneshmand S, So A, Chi KN, Murray N, Moore C, et al. Management of disseminated nonseminomatous germ cell tumors with risk-based chemotherapy followed by response-guided postchemotherapy surgery. J Clin Oncol. 2010;28:537–42.CrossRefGoogle Scholar
  8. 8.
    Saxman SB, Finch D, Gonin R, Einhorn LH. Long-term follow-up of a phase III study of three versus four cycles of bleomycin, etoposide, and cisplatin in favorable-prognosis germ-cell tumors: the Indian University experience. J Clin Oncol. 1998;16:702–6.CrossRefGoogle Scholar
  9. 9.
    Honecker F, Aparicio J, Berney D, Beyer J, Bokemeyer C, Cathomas R, et al. ESMO Consensus Conference on testicular germ cell cancer: diagnosis, treatment and follow-up. Ann Oncol. 2018;29:1658–86.CrossRefGoogle Scholar
  10. 10.
    Beck SD, Foster RS. Management of the post chemotherapy subcentimeter residual mass: the case for observation. World J Urol. 2009;27:485–8.CrossRefGoogle Scholar
  11. 11.
    Sheinfeld J. Risks of the uncontrolled retroperitoneum. Ann Surg Oncol. 2003;10:100–1.CrossRefGoogle Scholar
  12. 12.
    Daneshmand S, Djaladat H, Nichols C. Management of residual mass in nonseminomatous germ cell tumors following chemotherapy. Ther Adv Urol. 2011;3:163–71.CrossRefGoogle Scholar
  13. 13.
    Geldart TR, Gale J, McKendrick J, et al. Late relapse of metastatic testicular nonseminomatous germ cell cancer: surgery is needed for cure. BJU Int. 2006;98:353–8.CrossRefGoogle Scholar
  14. 14.
    Beck SD, Foster RS, Bihrle R, et al. Teratoma in the orchiectomy specimen and volume of metastasis are predictors of retroperitoneal teratoma in post-chemotherapy nonseminomatous testis cancer. J Urol. 2002;168:1402–4.CrossRefGoogle Scholar
  15. 15.
    Stephenson AJ, Tal R, Sheinfeld J. Adjunctive nephrectomy at post-chemotherapy retroperitoneal lymph node dissection for nonseminomatous germ cell testicular cancer. J Urol. 2006;176:1996–9 discussion 1999.CrossRefGoogle Scholar
  16. 16.
    Cary KC, Beck SD, Bihrle R, Foster RS. Clinical and pathological features predictive of nephrectomy at post-chemotherapy retroperitoneal lymph node dissection. J Urol. 2013;189:812–7.CrossRefGoogle Scholar
  17. 17.
    Moore CJ, Daneshmand S, Kondagunta GV, Nichols CR. Management of difficult germ-cell tumors. Oncology (Williston Park). 2006;20:1565–70 1575; discussion 1575-1566.Google Scholar
  18. 18.
    Johnston P, Beck SD, Cheng L, et al. Incidence, histology and management of intraluminal thrombus at post-chemotherapy retroperitoneal lymph node dissection. J Urol. 2013;190:874–7.CrossRefGoogle Scholar
  19. 19.
    Duty B, Daneshmand S. Resection of the inferior vena cava without reconstruction for urologic malignancies. Urology. 2009;74:1257–62.CrossRefGoogle Scholar
  20. 20.
    Quinones-Baldrich W, Alktaifi A, Eilber F, Eilber F. Inferior vena cava resection and reconstruction for retroperitoneal tumor excision. J Vasc Surg. 2012;55:1386–93 discussion 1393.CrossRefGoogle Scholar
  21. 21.
    Beck SD, Lalka SG. Long-term results after inferior vena caval resection during retroperitoneal lymphadenectomy for metastatic germ cell cancer. J Vasc Surg. 1998;28:808–14.CrossRefGoogle Scholar
  22. 22.
    Tognoni PG, Foster RS, McGraw P, et al. Combined post-chemotherapy retroperitoneal lymph node dissection and resection of chest tumor under the same anesthetic is appropriate based on morbidity and tumor pathology. J Urol. 1998;159:1833–5.CrossRefGoogle Scholar
  23. 23.
    Restrepo CS, Eraso A, Ocazionez D, Lemos J, Martinez S, Lemos DF. The diaphragmatic crura and retrocrural space: normal imaging appearance, variants, and pathologic conditions. Radiographics. 2008;28:1289–305.CrossRefGoogle Scholar
  24. 24.
    Fadel E, Court B, Chapelier AR, Droz JP, Dartevelle P. One-stage approach for retroperitoneal and mediastinal metastatic testicular tumor resection. Ann Thorac Surg. 2000;69:1717–21.CrossRefGoogle Scholar
  25. 25.
    • Albany C, Adra N, Snavely AC, et al. Multidisciplinary clinic approach improves overall survival outcomes of patients with metastatic germ-cell tumors. Ann Oncol. 2018;29:341–6 This study showed that multidisciplinary clinic approach to GCT at high-volume cancer center is associated with improved OS outcomes. These finding are especially relevent to the surgical resection of residual mass after chemotherapy.CrossRefGoogle Scholar
  26. 26.
    Besse B, Grunenwald D, Flechon A, et al. Nonseminomatous germ cell tumors: assessing the need for postchemotherapy contralateral pulmonary resection in patients with ipsilateral complete necrosis. J Thorac Cardiovasc Surg. 2009;137:448–52.CrossRefGoogle Scholar
  27. 27.
    •• Calaway AC, Foster RS, Adra N, et al. Risk of bleomycin-related pulmonary toxicities and operative morbidity after postchemotherapy retroperitoneal lymph node dissection in patients with good-risk germ cell tumors. J Clin Oncol. 2018.  https://doi.org/10.1200/JCO.18.00431 This study showed that the inclusion of bleomycin does not increase the risk of pulmonary morbidity, operative difficulty, or nonpulmonary postoperative complications after PC-RPLND in men with IGCCCG good-risk GCT.
  28. 28.
    Cary KC, Pedrosa JA, Kaimakliotis HZ, Masterson TA, Einhorn LH, Foster RS. The impact of bleomycin on retroperitoneal histology at post-chemotherapy retroperitoneal lymph node dissection of good risk germ cell tumors. J Urol. 2015;193:507–12.CrossRefGoogle Scholar
  29. 29.
    Kundu SD, Feldman DR, Carver BS, Gupta A, Bosl GJ, Motzer RJ, et al. Rates of teratoma and viable cancer at post-chemotherapy retroperitoneal lymph node dissection after induction chemotherapy for good risk nonseminomatous germ cell tumors. J Urol. 2015;193:513–8.CrossRefGoogle Scholar
  30. 30.
    Fox EP, Weathers TD, Williams SD, Loehrer PJ, Ulbright TM, Donohue JP, et al. Outcome analysis for patients with persistent nonteratomatous germ cell tumor in postchemotherapy retroperitoneal lymph node dissections. J Clin Oncol. 1993;11:1294–9.CrossRefGoogle Scholar
  31. 31.
    Nichols CR, Williams SD, Loehrer PJ, Greco FA, Crawford ED, Weetlaufer J, et al. Randomized study of cisplatin dose intensity in poor-risk germ cell tumors: a Southeastern Cancer Study Group and Southwest Oncology Group protocol. J Clin Oncol. 1991;9:1163–72.CrossRefGoogle Scholar
  32. 32.
    Fizazi K, Tjulandin S, Salvioni R, Germà-Lluch JR, Bouzy J, Ragan D, et al. Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumors: prognostic factors and role of postsurgery chemotherapy--results from an international study group. J Clin Oncol. 2001;19:2647–57.CrossRefGoogle Scholar
  33. 33.
    •• Giannatempo P, Pond GR, Sonpavde G, et al. Treatment and clinical outcomes of patients with teratoma with somatic-type malignant transformation: an international collaboration. J Urol. 2016;196:95–100 International retrospective study that assessed the prognostic factors, treatments and outcomes in patients with malignant transformation of teratoma. CrossRefGoogle Scholar
  34. 34.
    Speir R, Cary C, Foster RS, Masterson TA. Management of patients with metastatic teratoma with malignant somatic transformation. Curr Opin Urol. 2018;28:469–73.PubMedGoogle Scholar
  35. 35.
    • Al-Hader AA, Jain A, Al-Nasrallah N, Einhorn LH. Metastatic malignant transformation of teratoma to primitive neuroectodermal tumor (PNET): results with PNET-based chemotherapy. Am J Clin Oncol. 2015;38:364–6 This study evaluated the role of chemotherapy with cyclophosphamide+doxorubicin+vincristine (CAV) alternating with ifosfamide+etoposide (IE) in malignant transformation of teratoma to primitive neuroectodermal tumor (PNET). CrossRefGoogle Scholar
  36. 36.
    Albany C, Einhorn LH. Extragonadal germ cell tumors: clinical presentation and management. Curr Opin Oncol. 2013;25:261–5.PubMedGoogle Scholar
  37. 37.
    Albany C. Current medical management of patients with poor-risk metastatic germ-cell tumors. Curr Opin Urol. 2018;28:474–8.PubMedGoogle Scholar
  38. 38.
    Adra N, Althouse SK, Liu H, Brames MJ, Hanna NH, Einhorn LH, et al. Prognostic factors in patients with poor-risk germ-cell tumors: a retrospective analysis of the Indiana University experience from 1990 to 2014. Ann Oncol. 2016;27:875–9.CrossRefGoogle Scholar
  39. 39.
    Schneider BP, Kesler KA, Brooks JA, Yiannoutsos C, Einhorn LH. Outcome of patients with residual germ cell or non-germ cell malignancy after resection of primary mediastinal nonseminomatous germ cell cancer. J Clin Oncol. 2004;22:1195–200.CrossRefGoogle Scholar
  40. 40.
    •• Ranganath P, Kesler KA, Einhorn LH. Perioperative morbidity and mortality associated with bleomycin in primary mediastinal nonseminomatous germ cell tumor. J Clin Oncol. 2016;34:4445–6 This study found high rate of post-operative pulmonary failure after bleomycin containing chemotherapy (BEP) in patients with PMNSGCTs. The results support the use of VIP in PMNSGCT patients prior to major thoracic surgical procedures. CrossRefGoogle Scholar
  41. 41.
    Kesler KA, Rieger KM, Hammoud ZT, Kruter LE, Perkins SM, Turrentine MW, et al. A 25-year single institution experience with surgery for primary mediastinal nonseminomatous germ cell tumors. Ann Thorac Surg. 2008;85:371–8.CrossRefGoogle Scholar
  42. 42.
    Becherer A. PET in testicular cancer. Methods Mol Biol. 2011;727:225–41.CrossRefGoogle Scholar
  43. 43.
    Bachner M, Loriot Y, Gross-Goupil M, Zucali PA, Horwich A, Germa-Lluch JR, et al. 2-(1)(8)fluoro-deoxy-D-glucose positron emission tomography (FDG-PET) for postchemotherapy seminoma residual lesions: a retrospective validation of the SEMPET trial. Ann Oncol. 2012;23:59–64.CrossRefGoogle Scholar
  44. 44.
    De Santis M, Becherer A, Bokemeyer C, et al. 2-18fluoro-deoxy-D-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: an update of the prospective multicentric SEMPET trial. J Clin Oncol. 2004;22:1034–9.CrossRefGoogle Scholar
  45. 45.
    Cathomas R, Klingbiel D, David Bernard B et al. FDG PET scan (PET) positive residual lesions after chemotherapy (chemo) for metastatic seminoma: results of an International Global Germ Cell Cancer Group (G3) registry. J Clin Oncol. 2017;359:4521–1.Google Scholar
  46. 46.
    Mezvrishvili Z, Managadze L. Retroperitoneal lymph node dissection for high-risk stage I and stage IIA seminoma. Int Urol Nephrol. 2006;38:615–9.CrossRefGoogle Scholar
  47. 47.
    Rice KR, Beck SD, Bihrle R, et al. Survival analysis of pure seminoma at post-chemotherapy retroperitoneal lymph node dissection. J Urol. 2014;192:1397–402.CrossRefGoogle Scholar
  48. 48.
    •• Adra N, Abonour R, Althouse SK, et al. High-dose chemotherapy and autologous peripheral-blood stem-cell transplantation for relapsed metastatic germ cell tumors: the Indiana University experience. J Clin Oncol. 2017;35:1096–102 This large study from Indiana University showed that patients with relapsed metastatic GCT can be cured with second-line and even third-line high-dose chemotherapy (HDCT) and peripheral-blood stem-cell transplantation (PBSCT). Relapsed seminoma had high response rate with 90% cure with HDCT. CrossRefGoogle Scholar
  49. 49.
    Albany C, Einhorn L. Pitfalls in management of patients with germ cell tumors and slight elevation of serum alpha-fetoprotein. J Clin Oncol. 2014;32:2114–5.CrossRefGoogle Scholar
  50. 50.
    Garnick MB. Spurious rise in human chorionic gonadotropin induced by marihuana in patients with testicular cancer. N Engl J Med. 1980;303:1177.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of MedicineIndiana University School of MedicineIndianapolisUSA
  2. 2.Department of SurgeryIndiana University School of MedicineIndianapolisUSA
  3. 3.Department of UrologyIndiana University School of MedicineIndianapolisUSA

Personalised recommendations